N Z Med J. 2025 Nov 7;138(1625):13-19. doi: 10.26635/6965.7129.
ABSTRACT
AIM: Endoscopic submucosal dissection (ESD) has become a well-established treatment option for premalignant and early malignant lesions of the gastrointestinal tract. This study aimed to evaluate the recurrence rate following ESD in a single tertiary centre cohort of patients.
METHODS: All consecutive patients who received ESD treatment for premalignant or early malignant lesions by a single endoscopist (AS) at Middlemore Hospital from 11 February 2019 to 6 October 2023 were included in this retrospective cohort study. The primary outcome was recurrence rate of premalignant and early malignant lesions of the gastrointestinal tract following ESD. Recurrence was defined as confirmed neoplasm on histopathology on first follow-up surveillance endoscopy. The target recurrence rate was less than or equal to 5%. Secondary outcome was recurrence stratified by location of the lesion, lesion size, en bloc resection status, R0 resection status and histopathological type of lesion.
RESULTS: A total of 119 ESD procedures were completed during the study time frame, with 91 having a surveillance endoscopy with a median time of 231 days. Twenty-eight cases did not have surveillance endoscopy completed. Three (3.3%) had recurrence of disease, of which two were oesophageal squamous cell carcinoma and one was rectal sessile serrated adenoma. We were unable to ascertain any statistically significant associations with regard to our secondary outcome variables.
CONCLUSION: This study supports the efficacy of ESD in our centre as a curative treatment modality for premalignant and early malignant gastrointestinal lesions, demonstrating a recurrence rate within the acceptable international benchmark.
PMID:41197092 | DOI:10.26635/6965.7129
